Patent ID: 9717700
Date: 2017-08-01
CPC Classifications: A61K,A61P

Claim:
1. A method for treating a disorder modulated at least in part by opiate receptor activity or monoamine activity, comprising orally administering every six hours to a subject in need thereof a pharmaceutical composition consisting of a therapeutically effective amount of an active pharmaceutical ingredient and pharmaceutically acceptable carriers in a sustained release dosage form, wherein the active pharmaceutical ingredient consists of O-desmethyltramadol (M1), or a pharmaceutically acceptable salt thereof, wherein the pharmaceutically acceptable carriers consist of a polymer selected from polysaccharide, acrylic resin, polyalkylene glycol, polyvinyl acetate, polyvinylpyrrolidone, protein-derived materials, colloidal silica, and mixtures thereof, 25-90 wt % of microcrystalline cellulose; and, optionally, one or more pharmaceutical excipients selected from the group consisting of salts and magnesium stearate; and wherein the mean difference between minimum and maximum plasma concentration of M1 at steady state (ΔCss) is not more than 40 ng/ml.